The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome
Status:
Recruiting
Trial end date:
2027-03-31
Target enrollment:
Participant gender:
Summary
Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic.
The clinical mortality is as high as 30%-40%. At present, there is no specific treatment.
Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a
certain amount in normal human body, mainly synthesized by liver in infants and kidneys in
adults, which can stimulate erythropoiesis. In recent years, more and more studies have shown
that high-dose exogenous EPO administration has benefit effects on multi-organ protection.
Therefore, we designed this prospective, double-blind, placebo-controlled trial for defecting
EPO on the alveolar fluid clearance of ARDS. The study mainly answers the following
questions: Does human erythropoietin accelerate the resolution of alveolar edema in ARDS? Is
there any effect on hospital survival? The study will draw conclusions by comparing the
control group with the experimental group.
Phase:
N/A
Details
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University